Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company advancing targeted protein degradation therapies for immune-inflammatory diseases and oncology. This dedicated news hub provides investors and industry observers with timely updates on the company’s scientific progress, clinical developments, and strategic initiatives.
Access comprehensive coverage of KYMR’s innovative pipeline, including updates on STAT6 and IRAK4 degrader programs, partnership announcements, and financial disclosures. Our curated news collection enables efficient tracking of milestones in protein degradation research – from preclinical breakthroughs to clinical trial results – while maintaining strict adherence to factual reporting standards.
Key content categories include regulatory filings, peer-reviewed research highlights, executive leadership updates, and analysis of therapeutic platform advancements. All materials are sourced from verified channels to ensure reliability for investment research and sector analysis.
Bookmark this page for streamlined access to KYMR’s latest developments in transforming undruggable targets into viable treatment pathways through proprietary degradation technology. Check regularly for updates on oral small molecule therapies that aim to combine biologics-like efficacy with enhanced patient convenience.
Kymera Therapeutics (NASDAQ: KYMR) announced promising preclinical data at the ASH Annual Meeting regarding the efficacy of its STAT3 and IRAKIMiD degraders for treating specific blood cancers. Study results showed that a STAT3 degrader led to significant disease improvement in a model of cutaneous T-cell lymphoma (CTCL). Additionally, combining IRAKIMiDs with a BCL-2 inhibitor demonstrated strong antitumor effects in MYD88-mutant diffuse large B-cell lymphoma (DLBCL). These findings support the progression of both compounds into clinical trials.
Kymera Therapeutics (NASDAQ: KYMR) presented promising preclinical data for KT-253 at the ASH Annual Meeting, demonstrating its capability to induce rapid apoptosis and tumor regression in acute myeloid leukemia (AML) models. The data indicates that KT-253, in combination with the BCL-2 inhibitor venetoclax, yields durable tumor responses, even in venetoclax-resistant models. The compound also shows potential in other hematologic malignancies, such as DLBCL. Kymera anticipates entering clinical trials for KT-253, aimed at advancing treatment options for wild-type p53 cancers.
Kymera Therapeutics (NASDAQ: KYMR) announced a virtual investor event scheduled for December 14, 2022, where they will share clinical updates on their Phase 1 trial of the IRAK4 degrader KT-474. This trial targets patients with hidradenitis suppurativa or atopic dermatitis. Additionally, the company will discuss its oncology pipeline developments. Kymera focuses on targeted protein degradation to develop innovative therapies for various diseases, leveraging its proprietary Pegasus platform.
Kymera Therapeutics (NASDAQ: KYMR) announced substantial developments in its clinical programs and financial status. The company completed the patient cohort of the KT-474 Phase 1 trial, focusing on autoimmune diseases, and is on track for regulatory submissions for KT-253. In Q3 2022, Kymera raised $150 million in private equity, closing with a cash balance of $596 million, projected to sustain operations into 2025. However, collaboration revenues fell to $9.6 million from $20.3 million year-over-year, contributing to a net loss of $43 million.
Kymera Therapeutics (NASDAQ: KYMR) appointed Dr. Victor Sandor to its Board of Directors on November 3, 2022, to leverage his extensive experience in biopharmaceutical clinical development. Dr. Sandor, previously Chief Medical Officer at Array BioPharma, is expected to enhance Kymera’s capabilities in advancing targeted protein degradation therapies. The company acknowledged the contributions of retiring board member Don Nicholson, PhD, who has served for five years. Kymera aims to capitalize on its Pegasus platform to develop innovative treatments for various diseases.
Kymera Therapeutics (NASDAQ: KYMR) will announce its Q3 2022 financial results on November 3, 2022, hosting a conference call at 8:30 a.m. ET. The company is also set to participate in several investor conferences, including:
- Credit Suisse Annual Healthcare Conference on November 9
- Stifel Healthcare Conference on November 15
- Piper Sandler Healthcare Conference from November 29 to December 1
- Bank of America Biotech Conference on December 7
Access the call at kymeratx.com.
Kymera Therapeutics (NASDAQ: KYMR) has completed dosing in Part C of its Phase 1 clinical trial for KT-474, aimed at treating hidradenitis suppurativa (HS) and atopic dermatitis (AD). This Phase 1 trial showcases positive pharmacokinetics and safety results. Concurrently, the company continues dose escalation for KT-333 and KT-413, both targeting cancer indications. Additionally, IND enabling studies for KT-253 are complete, with an expected IND filing by year-end. A webcast on December 14 will present further details on clinical data and development pipelines.
Kymera Therapeutics (NASDAQ: KYMR) announced on September 15, 2022, that the FDA has granted orphan drug designation for its candidate KT-333 to treat Cutaneous T-cell Lymphoma (CTCL). This marks the second orphan designation for KT-333, which is a first-in-class STAT3 degrader. Currently, no approved therapies specifically target this pathway in CTCL. The FDA's designation allows for various development incentives such as tax credits and seven-year marketing exclusivity upon approval. The ongoing Phase 1 trial for KT-333 evaluates its safety in patients with aggressive lymphomas.
Kymera Therapeutics (NASDAQ: KYMR) announced that its Co-Founder, President, and CEO, Nello Mainolfi, will participate in several upcoming investor conferences. Key events include the 2022 Wells Fargo Healthcare Conference on September 7 at 1:20 p.m. ET, the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 8:00 a.m. ET, and the 2022 Guggenheim Nantucket Therapeutics Conference on September 28 at 2:15 p.m. ET. Presentation webcasts will be accessible on Kymera's website, with archived replays available for 90 days.
Kymera Therapeutics (NASDAQ: KYMR) has announced a PIPE financing, issuing 2,769,228 shares of common stock at $26.00 each and pre-funded warrants for 3,000,000 shares at $25.9999. The anticipated gross proceeds of approximately $150 million will support ongoing R&D and general corporate needs. The financing is led by notable healthcare investors and is expected to close on August 22, 2022. Following the transaction, Kymera's cash reserves are projected to exceed $600 million by August 31, 2022.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
